Navigation Links
Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
Date:2/29/2008

ng role in revolutionizing the molecular diagnostics field."

Mr. Avniel said the three tests will differentiate squamous from non-squamous cell lung cancer; differentiate mesothelioma from adenocarcinoma; and identify the origin of a tumor in cancer of unknown primary (CUP). These tests, applying Rosetta Genomics microRNA technology, will be validated and offered by clinical laboratories that are state-licensed and CLIA-certified, as applicable.

The tests based on Rosetta Genomics' microRNA technology share three common features. First, they are designed to offer clinicians standardized, objective diagnostic information. Second, they are designed to assist clinicians in determining the most appropriate treatment for patients. Third, the tests are backed by a strong pharmacoeconomic rationale. "We are constantly expanding our diagnostic pipeline, both through collaborations as well as internally, with tests aimed to fulfill these three objectives," Mr. Avniel said.

Mr. Avniel noted that 2007 also saw continued progress in Rosetta Genomics' microRNA-based therapeutics program for liver cancer, conducted in collaboration with Isis Pharmaceuticals, with in vivo studies initiated.

Mr. Avniel added that concerning intellectual property, Rosetta Genomics "has continued to strengthen its portfolio this year, with 2 patents issued, 2 patents allowed, and 22 applications under active examination, as well as four new patent applications filed during Q4 of 2007."

Financial Overview

Operating loss for the fourth quarter of 2007 was $3.5 million (including a non-cash expense of $311,000 related to stock based compensation), compared with an operating loss of $2.2 million (including a non-cash expense of $302,000 related to stock based compensation), for the corresponding quarter of 2006. Operating loss for the year ended December 31, 2007 was $11 million (including a non-cash expense of $1 million related to stock based compensation), com
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Rosetta Genomics Establishes Medical Advisory Board
2. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
3. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
4. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
5. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
6. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
7. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... one of the most promising technologies for future quantum ... (photons) instead of electrons. First, it is necessary to ... and control their direction. Researchers around the world have ... but now scientists at the Niels Bohr Institute have ... one at a time and in a particular direction. ...
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... Research “Global Orthobiologics Market” the global orthobiologics market was valued ... reach a market worth USD 5,519.9million in 2019at a CAGR ... the population aged 50 years and above is afflicted by ... almost double by the year 2020. This has and will ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the six months ended ... expressed in Canadian dollars and presented under International ... 2014 Highlights , Announced top-line results ... primary endpoint for subjects enrolled in the Phase ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Three ... Energy's 2014 Hydrogen Production R&D Award ... by splitting water using sunlight. , Shared with ... and the University of Nevada, Las Vegas (UNLV), ... developing models of photoelectrochemical solar-hydrogen production and corrosion ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Livermore Team Awarded for Hydrogen Production Research 2
... INDIANAPOLIS, Sept. 23 The volume of biological samples ... pharmaceutical and biotechnology industries shift their focus from traditional ... and biomarkers in the discovery process has put an ... the practices that life sciences companies employ to collect, ...
... Pharmaceutical and Biotech Trainers (SPBT) today announced that Kevin ... October 1.  He brings to his new role significant ... Mr. Kruse will be responsible for leading ... organization that represents more than 1,000 members in the ...
... 23, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 2BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 3BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 4BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 5BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 6BioSpain 2010 Will Host 2,000 Business Meetings in Which More Than 600 Companies Will Come Together 7
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/31/2014)... Climate Change , suggests that if current trends continue ... global targets for total greenhouse gas (GHG) emissions in 2050. ... carefully about the food we choose and its environmental impact. ... one of a number of actions that need to be ... enough food for all. , As populations rise and ...
(Date:8/31/2014)... in French . ... in the prestigious Nature Neuroscience journal by, Sylvain ... the Douglas Mental Health University Institute and McGill University, opens ... dynamic mechanisms controlling memory as well of the role of ... the subiculum. , In 2009, they developed a unique ...
Breaking Biology News(10 mins):Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2
... genome-wide association study published today in Nature Genetics ... in eight blood measurements and the impact those variants ... the number and volume of cells in the blood, ... disorders, including anaemia, infection and blood cell cancers. ...
... of human papillomavirus is seen across the population of India, ... vaccination targeting these types could eliminate 75 percent of the ... the American Association for Cancer Research Frontiers in Basic Cancer ... the most common cancer among Indian women, with an estimated ...
... across the Panama Canal in a Boston Whaler may sound ... of this story brandishes a butterfly net and studies the ... Tropical Research Institute. , "Our long-term study shows ... migrations," said Robert Srygley, former Smithsonian post doctoral fellow who ...
Cached Biology News:Blood counts are clues to human disease 2Blood counts are clues to human disease 3Scientists identify common HPV genotypes in northern India, encourage vaccination 2Panama butterfly migrations linked to El Nio, climate change 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: